Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Glecaprevir/Pibrentasvir Tx in Renal & CV Outcomes

Infect Dis Ther; ePub 2018 Oct 27; Tran, et al

In patients with chronic hepatitis C (CHC) without cirrhosis, short-duration treatment with glecaprevir/pibrentasvir (G/P) resulted in stable renal function and improvements in cardiovascular (CV) and metabolic extrahepatic manifestation (EHM) markers, especially in those with severe EHMs at baseline. This according to a post-hoc analysis of 2 phase 3 clinical trials in patients without cirrhosis treated with G/P for 8 weeks. In addition, 1 phase 3 trial was carried out to explore the effects of treatment on renal EHMs in patients with advanced renal impairment at baseline. Researchers included all CHC patients treated with G/P for 8 or 12 weeks enrolled across 5, phase 3 trials as a sensitivity analysis. They found:

  • G/P treatment for 8 weeks resulted in statistically significant declines in triglycerides (‒28.6 mg/dL) and glucose (‒11.2 mg/dL), with no statistically significant decline in estimated glomerular filtration rate (eGFR).
  • Biomarker improvements were greatest among patients with elevated triglycerides and elevated glucose at baseline.
  • Similar effects were observed across all patients treated with G/P for 8 or 12 weeks.

Citation:

Tran TT, Mehta D, Mensa F, Park C, Bao Y, Sanchez Gonzalez Y. Pan-genotypic hepatitis C treatment with glecaprevir and pibrentasvir for 8 weeks resulted in improved cardiovascular and metabolic outcomes and stable renal function: A post-hoc analysis of phase 3 clinical trials. [Published online ahead of print October 27, 2018]. Infect Dis Ther. doi:10.1007/s40121-018-0218-x.

This Week's Must Reads

CVD Events Prevented with New AHA BP Guideline, Circulation; ePub 2018 Nov 19; Bress, et al

USPSTF: Interventions to Prevent Child Maltreatment, JAMA; 2018 Nov 27; US Preventive Services Task Force

Team-Based Primary Care in Chronically Ill Patients, JAMA Intern Med; ePub 2018 Nov 26; Meyers, et al

Rotating Night Shift Work & Risk of T2D, BMJ; ePub 2018 Nov 21; Shan, Li, et al

PUFAs for Primary & Secondary CVD Prevention, Cochrane Library; ePub 2018 Nov 27; Abdelhamid, et al

Must Reads in Hepatitis

Glecaprevir/Pibrentasvir in HCV GT 3 Infection, J Viral Hepat; ePub 2018 Nov 12; Flamm, et al

HCV Therapy Reduces CVD Events in Veterans, Gastroenterology; ePub 2018 Nov 13; Butt, et al

Alcohol Use Disorder in Patients with HCV/HIV , Drug Alcohol Depend; 2018 Oct 30; Frost, et al

Sexually-acquired HCV in MSM Using PrEP, J Infect Dis; ePub 2018 Nov 20; Price, et al

Effective HCV Testing In US Prisons, Am J Prev Med; ePub 2018 Nov 19; Assoumou, et al